Actavis Pharma’s North American region includes the U.S. and Canada. In the United States, Actavis is currently the third-largest generic pharmaceutical company.
The Company’s strategy in the U.S. is to develop generic pharmaceuticals that are difficult to formulate or manufacture or will complement or broaden our existing product lines.
The Canadian generics market, with an estimated value of approximately $5 billion, is one of the largest generic pharmaceutical markets in the world. Generic pharmaceuticals are substituted at the pharmacy.
Actavis Pharma is currently # 6 in the Canadian generic pharmaceutical market with an approximate market share of 5%. We actively market our products to pharmacies through a team of 30 sales representatives.